Judge Rejects Motion To Overturn Verdict Upholding Amgen’s Cholesterol Drug Patents
Sanofi and Regeneron, which manufacture rival drugs, filed the suit against Amgen. In other industry news, the FDA investigates complaints of exploding batteries in e-cigarette devices.
Sanofi, Regeneron Lose Bid To Overturn Amgen Win In Patent Case
A federal judge on Tuesday refused to throw out a court verdict upholding two Amgen Inc patents related to the company's cholesterol drug, a defeat for Sanofi SA and Regeneron Pharmaceuticals Inc, which make a rival drug. In an October 2014 lawsuit, Amgen had sought to stop Paris-based Sanofi and Tarrytown, New York-based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9. (Pierson, 1/3)
The Associated Press:
FDA Probes Dangers Of Exploding E-Cigarette Batteries
The U.S. Food and Drug Administration is probing the dangers of exploding batteries in e-cigarettes, following dozens of reports of devices that have combusted, overheated or caught fire and sometimes injured users. (1/3)